Viridian Therapeutics Inc (VRDN) 13F Holders & Ownership Data (218 Funds, Q2 2026)

VRDN ranks #2788 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

VRDN is a top-conviction position for Kynam Capital Management, LP — at 6.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in VRDN belongs to FMR LLC, but the position matters far more to Kynam Capital Management, LP, who has 6.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Paradigm Biocapital Advisors LP has added to its VRDN position for two straight quarters, increasing it by $78.6M to reach $123.5M today.

Perceptive Advisors LLC has trimmed its VRDN position for two straight quarters, cutting it by $84.0M while still holding $10.7M.

VRDN is up 0.3% today, and institutions have been net buyers of $605.0M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

VRDN reported a net loss of $387.0M over the trailing twelve months.

• Not yet profitable — net loss of $387.0M over the trailing twelve months
• Revenue grew 175.5% year over year
• Net income declined year over year, from -$344.1M to -$387.0M
• Operating cash flow was negative, using $276.4M in cash
• Current ratio of 12.65x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.25x equity — within a conventional range